VIVO - Meridian Bioscience, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue196,082194,830188,832
Cost of Revenue68,29572,94871,589
Gross Profit127,787121,882117,243
Operating Expenses
Research Development13,81512,60512,552
Selling General and Administrative61,11353,21752,299
Non Recurring1,4811,4811,481
Total Operating Expenses---
Operating Income or Loss51,37856,06052,392
Income from Continuing Operations
Total Other Income/Expenses Net163-997-284
Earnings Before Interest and Taxes51,54155,06352,108
Interest Expense897897897
Income Before Tax50,64455,06352,108
Income Tax Expense18,41519,52317,365
Minority Interest---
Net Income From Continuing Ops32,22935,54034,743
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income32,22935,54034,743
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares32,22935,54034,743